New Metal-Protein Attenuating Compounds with Neurotrophic Properties as a Therapeutic Strategy in Alzheimer's Disease

具有神经营养特性的新型金属蛋白减毒化合物作为阿尔茨海默病的治疗策略

• 批准号: G0802503/1
• 负责人: Adina Teodora Michael-Titus
• 金额: $ 68.78万
• 依托单位: Queen Mary University of London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2010
• 资助国家: 英国
• 起止时间: 2010 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0802503%2F1
• 关键词: New; Metal; Protein; Attenuating; Compounds

Alzheimer?s disease (AD) is the most common form of dementia, a devastating disease characterised by the loss of mental function. Large numbers of patients are affected by this disease worldwide, and as the world population is aging, the impact of this disease is ever increasing. None of the drugs used to treat patients at present affect significantly the disease. There is evidence that in the brain of patients with Alzheimer?s disease there is an imbalance in the activity of metals such as zinc and copper. There is a high concentration of these metals in areas of the brain affected by the disease, and it is believed that this process is responsible for brain damage. There is evidence that drugs that can bind these metals and reduce their concentration could affect beneficially the patients, and change the disease course. We know already that this new type of drug is likely to be well-tolerated, and there are already some observations which support the idea that these drugs can improve significantly the mental deterioration in patients. Our project is to develop new and improved drugs which can bind excess metals and thus reduce the toxic processes in the brain of patients with dementia. The funding will help us choose the best compound which could be tested in the next few years in patients.

老年痴呆症？老年痴呆症（AD）是痴呆症的最常见形式，是一种以精神功能丧失为特征的毁灭性疾病。世界范围内有大量患者受到这种疾病的影响，随着世界人口老龄化，这种疾病的影响不断增加。目前用于治疗病人的药物对这种疾病没有明显的影响。有证据表明，在老年痴呆症患者的大脑中？这种病的发病原因是锌和铜等金属的活性不平衡。在受疾病影响的大脑区域中，这些金属的浓度很高，据信这一过程是造成脑损伤的原因。有证据表明，可以结合这些金属并降低其浓度的药物可以对患者产生有益的影响，并改变疾病进程。我们已经知道，这种新型药物可能耐受性良好，并且已经有一些观察结果支持这些药物可以显着改善患者的精神恶化。我们的项目是开发新的和改进的药物，可以结合多余的金属，从而减少痴呆症患者大脑中的毒性过程。这笔资金将帮助我们选择最好的化合物，这些化合物可以在未来几年内在患者身上进行测试。